1051 / 1708
AREN0532/AREN0533: 4-year EFS
NWTS-5
AREN0532/
AREN0533
Stage I/II LOH 74.9%
83.9%
Stage III/IV LOH 65.9%
91.5%
Grade 3 or higher hematological toxicity seen with Regimen M
in 60% of patients
Conclusion: Regimen M therapy improved EFS for Stage III/IV
FH with LOH 1p and 16q compared to historical comparison
group treated with DD4A. The benefit of DD4A for Stage I/II FH
LOH 1p and 16q is less clear.
Dix DB et al. J Clin Oncol 33, 2015 (suppl; abstr 10009)